Pion's FLUX technology combines traditional dissolution testing with robust methods for assessing the pharmaceutical absorption potential of APIs, development formulations or finished dosage products. The result is a single combined test that makes in vitro-in vivo correlation (IVIVC) testing and modeling more realistic - and more reliable.
With Pion FLUX, problems with the permeability and absorption potential of a promising compound can be identified far earlier in the development process. This saves time and helps you avoid costly clinical setbacks, meaning you can streamline the drug development process.
The Pion suite of In vitro absorption test equipment and Predictive Tools work in harmony to offer you fast, accurate and cost-effective results.
Drug development is a multi-step process that involves countless detours and unexpected challenges. Any misstep or delay can result in inaccurate findings, costly rework, and decreased product performance. At Pion, we make testing and formulation simpler and more efficient with our novel pharmaceutical absorption devices.
Assess the dissolution of finished drug product simultaneously with absorption potential for more predictive IVIVC modelling.
Pion’s dissolution-permeability apparatus for the simultaneous assessment of formulation drug release and absorption.
A powerful and versatile formulation workstation for automated analysis of solutions, powders, suspensions, compacted pellets and dosages in situ.
BioFLUX extends the utility of in-situ UV fiber-optic concentration monitoring, using biorelevant dissolution volumes of 200-250mL.
Our specialists provide scientific leadership and experience to solve problems faster. From PhysChem analysis to In vitro absorption testing, we’re with you every step of the way.
We develop honest and collaborative relationships with our customers. Our communication lines are always open for your inquiries or suggestions.
Using innovative pharmaceutical absorption test instruments, we deliver end-to-end capabilities for greater accuracy and fewer redundancies.